Covered recipient · General Payments record
CHIRAG J DALSANIA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$7,912.04
- Reported across 348 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,033.97 | 82 |
| Education | $15.50 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $228.74 | 12 |
| Daiichi Sankyo Inc. | $200.01 | 10 |
| Celgene Corporation | $161.05 | 7 |
| EMD Serono, Inc. | $112.31 | 4 |
| ABBVIE INC. | $102.66 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $97.00 | 4 |
| Genentech USA, Inc. | $96.40 | 3 |
| GlaxoSmithKline, LLC. | $82.65 | 4 |
| Merck Sharp & Dohme Corporation | $80.83 | 3 |
| Acerta Pharma LLC | $76.35 | 3 |
| Exelixis Inc. | $70.29 | 2 |
| Regeneron Healthcare Solutions, Inc. | $68.21 | 2 |
| Karyopharm Therapeutics Inc. | $65.68 | 2 |
| E.R. Squibb & Sons, L.L.C. | $59.45 | 3 |
| Gilead Sciences, Inc. | $57.75 | 2 |
| Janssen Biotech, Inc. | $56.83 | 2 |
| Alexion Pharmaceuticals, Inc. | $51.96 | 2 |
| EISAI INC. | $48.47 | 2 |
| Astellas Pharma US Inc | $44.97 | 2 |
| Stemline Therapeutics Inc. | $42.77 | 1 |
| JAZZ PHARMACEUTICALS INC. | $35.92 | 1 |
| PharmaEssentia USA Corporation | $31.96 | 1 |
| GENZYME CORPORATION | $31.21 | 1 |
| Tempus AI, Inc | $29.36 | 1 |
| Ipsen Biopharmaceuticals, Inc | $28.16 | 1 |
| ImmunoGen, Inc. | $27.49 | 1 |
| Agios Pharmaceuticals, Inc. | $23.07 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $19.17 | 1 |
| SERVIER PHARMACEUTICALS LLC | $18.75 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (83)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.